STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
26 June 2025, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist Dr. Eric Martin, PhD, as Chief Development Officer (CDO).
Dr. Martin has over 20 years of experience in oncology research and drug development spanning both academia and industry. He specializes in biomarker-enabled preclinical discovery and clinical development strategies for targeted and immunomodulatory cancer therapies.
